Boulder, Colo.

Went public on 11/17/00 at $7.50 per share

Filing Range: 6.0 million shares @ $8 to $9

Shares Outstanding: 21.5 million shares

Underwriters: Lehman Brothers/Deutsche Banc Alex. Brown/ Legg Mason Wood Walker

Company Counsel: Hogan & Hartson

Manager Counsel: Latham & Watkins

Auditor: Ernst & Young LLP

The Company:

Provides products and services for accelerating drug discovery. The company develops drug discovery/drug intermediates and is creating a collection of several hundred thousand novel small molecule compounds. The company performs research services to the biotechnology and pharmaceutical industries in medicinal chemistry, combinatorial chemistry, high-throughput screening and structure-based drug design. Its software is used to design sub-libraries that provide superior pharmacological properties and are biased to interact with specific biological mechanistic targets.

Venture Backers:

Mosaix Ventures LLC

HarbourVest Partners LLC.

Frazier & Co.

Boulder Ventures Ltd.

ARCH Venture Partners

Vector Fund Management LP

Mitsui & Co. Ltd.

Advent International Corp.

Financing Rounds:

Number of Round Amt.

Round # Round Date Stage Investors ($ thousands)

1 04/01/1998 2 Early Stage 1000.0

2 08/07/1998 5 Early Stage 6500.0

3 11/16/1999 6 Expansion 8000.1

4 08/31/2000 5 Expansion 10000.0


(Data in $ millions)



Total Revenues: 6.8

Net Income: 4.7